# Utomilumab

Source: https://onco.cc/drugs/utomilumab/  
OnCo record `utomilumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer.

## Summary

Utomilumab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by Pfizer, in ovarian cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Utomilumab: https://clinicaltrials.gov/search?intr=Utomilumab

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing](https://onco.cc/trials/nct05059522/)

---
JSON: https://onco.cc/api/v1/entities/utomilumab.json